By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Orchid Cellmark today reported an 18 percent jump in revenues year over year for the third quarter, led by a boost in its UK business.

For the three months ended Sept. 30, the Princeton N.J.-based DNA testing service firm said revenues totaled $17.3 million, compared to $14.7 million a year ago. In the UK, total revenues increased 44 percent year over year, primarily as a result of a rise in its forensic business there.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.